Cabozantinib May Benefit Patients With Castration-Resistant Prostate Cancer
Posted on December 10, 2012
Wow! here is another medication for castrate resistant metastatic prostate cancer.
When I was a resident over 20 years ago, we had no medication after hormonal therapy.
It is great to see so many new medications that are effective.
Most impressive is the fact that it gave a 29 month survival advantage!!
Dr. Matthew Whang, MD, MBA
Cabozantinib May Benefit Patients With Castration-Resistant Prostate Cancer.
Medscape (12/7, Nelson) reports that the “treatment of castration-resistant prostate cancer (CRPC) with the new drug” Cometriq (cabozantinib) produced “unprecedented” results, according to a study published online in the Journal of Clinical Oncology. In the trial of 171 men with CRPC, the investigators found that of the “patients randomized to cabozantinib, 72% experienced regression in soft tissue lesions, and 68% of evaluable patients showed improvement on bone scan.” Meanwhile, there was “complete resolution in 12%.” Overall, the median “progression-free survival for the entire treatment period was estimated to be 29.4 weeks in cabozantinib-treated patients, 29.7 weeks in docetaxel-naïve patients (n = 97), and 23.9 weeks in patients who previously received docetaxel-based therapy (n = 74).”
Posted in Uncategorized